- Home
- ANAB vs ORIC Comparison
ANAB vs ORIC Comparison
Compare ANAB & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ORIC
- Stock Information
- Founded
- ANAB 2005
- ORIC 2014
- Country
- ANAB United States
- ORIC United States
- Employees
- ANAB N/A
- ORIC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- ANAB Health Care
- ORIC Health Care
- Exchange
- ANAB Nasdaq
- ORIC Nasdaq
- Market Cap
- ANAB 600.4M
- ORIC 633.7M
- IPO Year
- ANAB 2017
- ORIC 2020
- Fundamental
- Price
- ANAB $22.27
- ORIC $9.59
- Analyst Decision
- ANAB Buy
- ORIC Strong Buy
- Analyst Count
- ANAB 11
- ORIC 9
- Target Price
- ANAB $54.64
- ORIC $18.75
- AVG Volume (30 Days)
- ANAB 623.5K
- ORIC 498.9K
- Earning Date
- ANAB 11-05-2024
- ORIC 11-12-2024
- Dividend Yield
- ANAB N/A
- ORIC N/A
- EPS Growth
- ANAB N/A
- ORIC N/A
- EPS
- ANAB N/A
- ORIC N/A
- Revenue
- ANAB $57,172,000.00
- ORIC N/A
- Revenue This Year
- ANAB $207.49
- ORIC N/A
- Revenue Next Year
- ANAB N/A
- ORIC N/A
- P/E Ratio
- ANAB N/A
- ORIC N/A
- Revenue Growth
- ANAB 282.17
- ORIC N/A
- 52 Week Low
- ANAB $13.36
- ORIC $6.33
- 52 Week High
- ANAB $41.31
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- ANAB 42.41
- ORIC 52.76
- Support Level
- ANAB $18.03
- ORIC $8.11
- Resistance Level
- ANAB $22.94
- ORIC $8.90
- Average True Range (ATR)
- ANAB 1.37
- ORIC 0.74
- MACD
- ANAB 0.45
- ORIC -0.04
- Stochastic Oscillator
- ANAB 86.18
- ORIC 49.42
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.